Discover the connection between GLP-1 receptor agonists and cardiometabolic health improvements in this insightful post.

Abstract

In this educational post, I, Dr. Alex Jimenez, walk you through how heart failure and type 2 diabetes share deep physiological roots—and why understanding those connections transforms care. I synthesize the latest findings from leading researchers on SGLT2 inhibitors and GLP-1 receptor agonists, explaining how these revolutionary therapies are shifting our treatment paradigms from simple glucose management to comprehensive cardiovascular risk reduction. I will translate how trial data informs our clinical decisions across different heart failure phenotypes and show how we translate this science into real-world, team-based care through two detailed clinical case studies.

I will also describe our unique, multidisciplinary model at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. Here, I collaborate closely with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine) (NPI #1164426749, Texas MD License #J2933). Together, we integrate chiropractic care, internal medicine, functional medicine, rehabilitation, and personal injury services to optimize outcomes for patients with complex cardiometabolic disease. You will find clear explanations of pathophysiology, practical treatment reasoning, safety and monitoring strategies, and a detailed look at how integrative chiropractic care supports cardiovascular and metabolic resilience throughout the patient journey.

Introducing Our Collaborative Model Of Care In El Paso, Texas

As a healthcare provider dedicated to a holistic and integrative approach, I practice in a multidisciplinary setting at Injury Medical Clinic PA in El Paso, Texas. Our team is built around medically integrated care for complex conditions—especially when musculoskeletal, neurologic, metabolic, and cardiovascular issues intersect. This multidisciplinary setup, common in modern injury and integrative clinics, allows us to align the best of internal medicine, evidence-based pharmacology, and conservative care.

• Medical Leadership: Our Medical Director and Collaborative Physician is Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, with over 40 years of experience as an internist. Dr. Cardenas provides the essential medical direction and oversight for diagnostics, medication management, cardiometabolic risk stratification, and interprofessional care plans.
• Chiropractic and Functional Medicine: I, Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, lead our integrative chiropractic, functional medicine, and rehabilitation services. My clinical observations and approach are informed by ongoing practice insights that I share publicly (Jimenez, n.d.-a; Jimenez, n.d.-b).
• Rehabilitation and Injury Care: We deliver structured rehabilitation, neuromuscular re-education, and movement therapy tailored to cardiometabolic safety, particularly for patients recovering from injury or living with heart failure (HF) and type 2 diabetes (T2D).
• Integrated Objectives: Our goals include optimizing cardiometabolic function, reducing pain and autonomic stress, improving endothelial health and mobility, and aligning guideline-directed medical therapy with lifestyle and biomechanical interventions.

Why this model matters: Heart failure and T2D are tightly interwoven. Combining internal medicine oversight with chiropractic and functional approaches allows us to address hemodynamics, autonomic tone, inflammatory load, biomechanics, glycemic control, and patient adherence in one cohesive plan.

The Paradigm Shift in Managing Cardiometabolic Health

For years, the primary goal in treating type 2 diabetes was centered almost exclusively on lowering blood glucose, measured by the A1C. While essential, this narrow focus often overlooked the bigger picture: the profound and bidirectional relationship between diabetes and cardiovascular disease. Today, a monumental shift is underway. We are moving beyond simple glucose management and embracing a strategy that prioritizes cardiovascular risk reduction. This change was born from a crucial FDA mandate in 2008, which required that new diabetes medications be rigorously tested to prove they were not only safe for the heart but also did not increase cardiovascular risk.

What followed was a series of large-scale clinical trials that delivered astonishing, unexpected results. Instead of merely demonstrating safety, these new drug classes—specifically SGLT2 inhibitors and GLP-1 receptor agonists—have demonstrated significant cardiovascular and renal benefits, fundamentally altering our approach to patient care.

The Heart Failure–Diabetes Connection: Why Physiology Guides Therapy

When I evaluate a patient with T2D who is trending toward HF—or is already symptomatic—I begin with physiology. This is where treatment decisions truly make sense.

• The Diabetic Milieu:

• • Hyperglycemia initiates metabolic stress.
  • Insulin resistance leads to compensatory hyperinsulinemia.
  • The combination fosters chronic inflammation, endothelial dysfunction, dyslipidemia, and elevated free fatty acid levels.

• Cardiovascular Remodeling:

• • Chronic metabolic stress and elevated neurohormonal drive (notably RAAS and sympathetic activation) promote left ventricular hypertrophy (LVH), fibrosis, and microvascular dysfunction.
  • Over time, patients may develop diabetic cardiomyopathy—a phenotype that can arise independent of obstructive coronary disease due to interstitial fibrosis, mitochondrial stress, and impaired myocardial substrate utilization.

• Epicardial Adipose Tissue as a Driver:

• • Expanded epicardial fat is metabolically active and highly pro-inflammatory, contributing to myocardial stiffness, microvascular dysfunction, and atrial arrhythmias.

From a systems view, diabetes and HF are not isolated conditions; they are reciprocal amplifiers. Every strategy we choose must target inflammatory signaling, hemodynamics, substrate metabolism, and autonomic balance.

Understanding Heart Failure Phenotypes To Personalize Care

I stratify heart failure across two principal phenotypes to align therapy with physiology:

• Heart failure with preserved ejection fraction (HFpEF, EF ? 50%)

• • Core features: Diastolic dysfunction, concentric LVH, increased stiffness, microvascular inflammation, and systemic fibrosis.
  • Common associations: Obesity, T2D, hypertension, atrial fibrillation, chronic kidney disease.
  • Clinical focus: Decongestion; blood pressure and lipid control; glycemic control; weight reduction; and agents with proven CV and renal benefit—including SGLT2 inhibitors.

• Heart failure with reduced ejection fraction (HFrEF, EF < 40%)

• • Core features: Reduced contractility, eccentric remodeling, ventricular dilation, high neurohumoral activation (RAAS and SNS).
  • Clinical focus: Quadruple therapy: ARNI, SGLT2 inhibitor, beta-blocker, and MRA, alongside risk factor modification and careful volume management.

In both phenotypes, inflammation, autonomic imbalance, and metabolic inflexibility are key targets. This is where modern pharmacology intersects meaningfully with integrative chiropractic care and functional medicine.

SGLT2 Inhibitors: Beyond Glucose Control to Heart Protection

The first class of drugs we will discuss is the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, such as dapagliflozin (Farxiga) and empagliflozin (Jardiance). These medications work in the kidneys to block the reabsorption of glucose, causing excess sugar to be excreted in the urine. While this effectively lowers blood sugar, robust trials have shown that it does much more.

Mechanism Highlights

• Renal Tubular Effects: Inhibits sodium-glucose co-transporter 2 in the proximal tubule, increasing urinary glucose and sodium losses, promoting natriuresis and mild osmotic diuresis. This reduces preload and improves vascular hemodynamics.
• Glomerular Benefit: Restoration of tubuloglomerular feedback reduces intraglomerular pressure, slowing glomerular hyperfiltration, fibrosis, and CKD progression.
• Myocardial Energetics: Low-level ketosis provides a more efficient fuel substrate for the failing heart, which often struggles to utilize glucose effectively. Improved mitochondrial function and reduced oxidative stress support contractile efficiency.
• Vascular and Plaque Stability: Improved endothelial function and plaque stabilization reduce ischemic events and enhance microvascular flow.
• Metabolic Improvements: Modest weight loss, lower uric acid, and decreased inflammatory signaling contribute to broader cardiometabolic gains.
• Epicardial Adipose Modulation: By reducing visceral and epicardial fat burden, SGLT2 inhibitors attenuate local myocardial inflammation and stiffness.

Evidence That Guides Practice: What The Trials Show

Select trial insights that inform our protocols:

• DAPA-HF and EMPEROR-Reduced: These landmark trials in HFrEF (with and without T2D) showed that SGLT2 inhibitors dramatically reduce the risk of hospitalization for heart failure and cardiovascular death, with significant relative risk reductions of approximately 25–26% (McMurray et al., 2019; Packer et al., 2020).
• EMPEROR-Preserved: This was a game-changer, demonstrating the first robust positive outcome for HFpEF, a condition historically difficult to treat. It reduced the composite of cardiovascular death or HF hospitalization (Anker et al., 2021).
• EMPA-KIDNEY and CREDENCE: These trials underscored the powerful kidney protection of SGLT2 inhibitors, showing significant reductions in CKD progression or CV death in patients with and without diabetes (The EMPA-KIDNEY Collaborative Group, 2023; Perkovic et al., 2019).
• SCORED and EMPULSE: Further trials strengthened the class-effect rationale across various clinical settings, including hospitalized patients (Bhatt et al., 2021).

The consistent finding across multiple trials is a remarkable 26-27% relative risk reduction in heart failure hospitalization, regardless of whether the patient has diabetes. This underscores that the protective mechanisms are not solely tied to glucose lowering but involve complex physiological processes that improve the heart’s function and structure.

GLP-1 Receptor Agonists: A Multifaceted Approach to Cardiometabolic Wellness

Next, we turn to the Glucagon-Like Peptide-1 (GLP-1) receptor agonists, a class that includes well-known drugs like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza). These drugs mimic the action of the natural incretin hormone GLP-1, offering a powerful, multifaceted approach to managing diabetes and cardiovascular health.

How GLP-1 Receptor Agonists Work

• Promote Satiety and Weight Loss: By slowing gastric emptying and signaling the brain to reduce appetite, GLP-1 agonists lead to significant and sustained weight loss. This reduction in visceral obesity is a key driver of their benefits.
• “Smart” Glucose Control: These drugs stimulate insulin release only when blood glucose is high, making them incredibly safe with a very low risk of hypoglycemia.
• Reduce Inflammation: GLP-1 agonists have been shown to lower systemic inflammation by lowering inflammatory markers such as C-reactive protein (CRP) and IL-6. This helps stabilize atherosclerotic plaques and improve endothelial function.
• Direct Cardiovascular Protection: Large cardiovascular outcome trials such as LEADER, SUSTAIN-6, and REWIND demonstrated impressive reductions in Major Adverse Cardiovascular Events (MACE)—a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke (Marso et al., 2016; Gerstein et al., 2019).
• Benefits Independent of Diabetes: The noteworthy SELECT trial studied semaglutide in patients with obesity and established cardiovascular disease. It demonstrated a 20% reduction in MACE, proving that cardiovascular benefits are driven by weight loss and anti-inflammatory effects beyond glucose control (Ryan et al., 2023).

Unraveling the Deeper Mechanisms: Why These Drugs Are So Effective

The profound benefits of GLP-1 receptor agonists stem from a complex interplay of metabolic, hemodynamic, and anti-inflammatory effects.

1. Reduced Endothelial Activation: Inflammation causes the lining of our blood vessels (the endothelium) to become sticky, allowing immune cells to form atherosclerotic plaques. GLP-1 agonists reduce this inflammation, slowing plaque formation.
2. Stable Plaques: By reducing macrophage infiltration and foam cell formation, these drugs help create more stable, less vulnerable plaques.
3. Improved Myocardial Energetics: GLP-1 signaling may help the heart muscle use glucose more efficiently and generate ATP. A more energy-efficient heart is a more resilient heart.
4. Cardiomyocyte Survival: These drugs may promote cardiomyocyte survival by reducing apoptosis (programmed cell death) and mitigating cellular stress.

The cumulative effect of these mechanisms—less inflammation, lower thrombotic risk, improved hemodynamics, and better glycemic control—explains the powerful reduction in cardiovascular events seen in clinical trials.

Applying Guideline-Directed Therapy Through Two Clinical Cases

To illustrate how we operationalize this evidence, I will share a practical, first-person walkthrough of two complex, real-world cases that reflect the challenges of modern cardiometabolic care.

Case 1: James—LADA, Obesity, CAD, and HFmrEF

James is a 57-year-old man with autoimmune type 1 diabetes (LADA), confirmed by positive GAD antibodies and unmeasurable C-peptide. His BMI is 38, a case of “double diabetes” where autoimmune disease coexists with obesity and insulin resistance. His profile includes:

• Cardiometabolic Profile: BP 136/88 mmHg, EF 48% (HFmrEF), eGFR 48 mL/min (CKD 3a), LDL 110 mg/dL.
• Current Medications: Losartan 25mg, Pravastatin 20mg, and an insulin pump.

Therapeutic Priorities and Our Collaborative Plan:

1. Intensify Statin Therapy: For a patient with diabetes and established ASCVD, a high-intensity statin is standard. Pravastatin 20 mg is not. Under Dr. Cardenas’s medical direction, we transition to high-intensity rosuvastatin to lower LDL below 70 mg/dL and leverage its potent anti-inflammatory effects (Sabatine et al., 2017).
2. Optimize Blood Pressure: Losartan 25 mg is subtherapeutic. We titrate it to 50-100 mg daily to achieve a target <130/80 mmHg, thereby providing nephroprotection and reducing cardiac afterload (KDIGO, 2021).
3. Consider an SGLT2 Inhibitor (Off-Label): Although not FDA-approved for type 1 diabetes due to the risk of euglycemic DKA, the cardiorenal benefits are compelling for James. With Dr. Cardenas’ oversight and shared decision-making, we may consider it with intensive patient education on sick-day rules, ketone monitoring, and hydration.
4. Consider a GLP-1 Receptor Agonist: To address his obesity and ASCVD risk, it is a strong candidate. We pursue coverage under obesity or NAFLD/NASH indications, titrate slowly to manage GI effects, and leverage its proven benefits in MACE reduction.

Case 2: Karen—HFrEF, Stage 4 CKD, T2D, and COPD

Karen is a 70-year-old woman with EF 30% (HFrEF), eGFR 24 mL/min (CKD 4), T2D, and COPD. Her BP is low at 90/70 mmHg, but she is well-compensated. She is already on quadruple therapy (ARNI, beta-blocker, MRA) plus a loop diuretic.

Therapeutic Priorities and Our Collaborative Plan:

1. Add an SGLT2 Inhibitor: strongly indicated. Evidence supports its use down to an eGFR of 20 mL/min for initiation, with proven benefits in reducing HF hospitalizations and slowing CKD progression (Heerspink et al., 2020). We anticipate an initial transient dip in eGFR, which is a sign of a protective hemodynamic reset rather than kidney injury.
2. Reduce Loop Diuretic: SGLT2 inhibitors have a diuretic effect. To prevent over-diuresis and hypotension in a stable patient like Karen, our rule of thumb is to reduce the loop diuretic dose by ~50% when starting an SGLT2 inhibitor and monitor her weight and symptoms closely.
3. Maintain MRA Therapy: SGLT2 inhibitors may blunt the risk of MRA-related hyperkalemia, so we maintain this life-saving HFrEF therapy while monitoring potassium levels (Vardeny & Vaduganathan, 2020).

Safety, Monitoring, And Interprofessional Coordination

Introducing these medications requires thoughtful oversight, which is central to our collaborative model.

• SGLT2 inhibitors: We monitor eGFR, electrolytes, and volume status. Patients are counseled on genital mycotic infection risk and, crucially, on sick-day protocols to prevent ketoacidosis. We establish clear rules for when to pause the medication for procedures or acute illness.
• GLP-1 receptor agonists: We start at a low dose and titrate slowly to mitigate GI effects. Hydration status is assessed, especially in HF patients sensitive to preload changes.
• Team-Based Strategies:

• • Cardenas ensures medical safety, lab tracking, and careful adjudication of polypharmacy.
  • As a chiropractor and functional medicine clinician, I coordinate movement prescriptions, nutrition frameworks, and autonomic regulation to align with cardiometabolic goals.
  • Our rehab specialists adjust activity based on ejection fraction, NYHA class, and comorbidities.

---

Optimizing Your Wellness- Video

---

How Integrative Chiropractic Care Complements Cardiometabolic Therapy

Chiropractic care in our clinic is not a standalone solution; it is a precision-fit component within a cardiometabolic framework, amplifying the benefits of medical therapy.

• Autonomic Regulation and Vascular Tone: Gentle, patient-specific spinal and soft-tissue techniques can reduce sympathetic overdrive and support vagal tone. My clinical observations show improved heart rate variability (HRV) readings after multi-session care plans, suggesting a tilt toward parasympathetic recovery—beneficial for HF and metabolic function.
• Pain Reduction and Inflammation: Chronic pain elevates catecholamines and inflammatory cytokines. By addressing mechanical pain generators (facet dysfunction, myofascial trigger points), we reduce a significant source of systemic stress, which may lower inflammation and improve exercise adherence.
• Structural and Biomechanical Support: As patients on GLP-1 RAs lose weight, their center of gravity and joint mechanics shift. Chiropractic adjustments help ensure the spine and joints remain aligned, preventing pain and dysfunction. This is crucial for enabling the increased physical activity observed in trials such as STEP-HFpEF, where patients reported fewer limitations and improved exercise function (Kosiborod et al., 2023).
• Respiratory Mechanics: For patients like Karen with COPD and HF, thoracic mobility work and diaphragmatic training aid lymphatic flow and oxygenation, thereby improving ventilatory efficiency and reducing orthopnea.

Functional Medicine Lens: Fueling Mitochondria And Modulating Inflammation

• Nutrition: We emphasize low-glycemic, fiber-rich dietary patterns to target insulin sensitivity, endothelial health, and mitochondrial function. We individualize sodium guidance, moving away from rigid restrictions toward a focus on whole foods and euvolemia driven by guideline-directed medications (Bozkurt et al., 2021).
• Micronutrients and Sleep: We evaluate and correct for deficiencies in iron, magnesium, and vitamin D. We also screen for and address sleep apnea, a major driver of sympathetic overdrive and insulin resistance.

Clinical Observations From Practice

Across my clinical work, a consistent pattern emerges, reinforcing the value of our integrated approach (Jimenez, n.d.-a; Jimenez, n.d.-b):

• When SGLT2 therapy is combined with targeted weight management and gentle, progressive movement, HFpEF symptoms like exertional dyspnea often improve within weeks.
• Patients with chronic pain and T2D adhere better to cardio-protective medications after their pain is reduced, likely due to improved sleep and decreased sympathetic arousal.
• In those with peripheral neuropathy, restoring gait mechanics reduces fall risk and increases daily step counts, thereby reinforcing the metabolic benefits of SGLT2 and GLP-1 therapies.

Putting It All Together: A Practical Takeaway

At Injury Medical Clinic PA, under the medical direction of Dr. Maria Guadalupe Cardenas, MD, we strive to combine the best contemporary cardiometabolic evidence with hands-on, patient-centered integrative care.

• Start with physiology: Understand the HF phenotype and the diabetic milieu.
• Use the right pharmacology: SGLT2 inhibitors for both HF phenotypes and CKD protection; GLP-1 RAs for weight and ASCVD risk, especially in HFpEF with obesity.
• Coordinate care: Internal medicine oversight by Dr. Cardenas ensures safety; integrative chiropractic and functional medicine enhance autonomic balance, mobility, and adherence.
• Monitor closely: Labs, hemodynamics, symptoms, and functional capacity guide safe progression.
• Personalize: Align interventions with the patient’s goals, capacity, and evolving clinical picture.

By uniting precise pharmacology with chiropractic, rehabilitation, and functional medicine, we can transform outcomes for patients who live at the intersection of heart failure and type 2 diabetes—one integrative step at a time.

References

• Anker, S. D., Butler, J., Filippatos, G., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Bhatt, D. L., Szarek, M., Pitt, B., et al. (2021). Sotagliflozin in patients with diabetes and chronic kidney disease. New England Journal of Medicine, 384(2), 129–139.
• Bozkurt, B., Coats, A. J. S., Tsutsui, H., et al. (2021). Universal definition and classification of heart failure: A report of the Heart Failure Society of America et al. Journal of Cardiac Failure, 27(4), 387–413.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet, 394(10193), 121–130.
• Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation, 139(25), e1082–e1143.
• Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436–1446.
• Jimenez, A. (n.d.-a). Clinical observations and integrative protocols. Personal Injury Doctor Group.
• Jimenez, A. (n.d.-b). Clinical profile and research interests. LinkedIn.
• Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., et al. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 389(12), 1069-1084.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
• Packer, M., Anker, S. D., Butler, J., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413–1424.
• Perkovic, V., Jardine, M. J., Neal, B., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). New England Journal of Medicine, 380(24), 2295–2306.
• Ryan, D. H., Lingvay, I., Colhoun, H. M., et al. (2023). Semaglutide effects on cardiovascular outcomes in people with overweight or obesity. New England Journal of Medicine, 389(24), 2221-2232.
• Sabatine, M. S., Giugliano, R. P., Keech, A. C., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713–1722.
• The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117–127.
• Vardeny, O., & Vaduganathan, M. (2020). Practical considerations for SGLT2 inhibitor use: Confronting therapeutic inertia and improving patient selection. Circulation, 142(25), 2399–2402.
• Zelniker, T. A., & Braunwald, E. (2018). Cardiac and renal transporters/sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. Journal of the American College of Cardiology, 72(15), 1845–1855.
• Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular disease, type 2 diabetes, heart failure, integrative chiropractic care, functional medicine, HFpEF, HFrEF, HFmrEF, cardiometabolic health, Dr. Alex Jimenez, Dr. Maria Cardenas, semaglutide, dapagliflozin, empagliflozin, weight loss, MACE reduction, El Paso TX, rehabilitation, polypharmacy, CKD, type 1 diabetes LADA, autonomic regulation, euglycemic DKA, sick day rules, internal medicine collaboration, El Paso Injury Medical Clinic PA, personal injury care, NAFLD NASH, lipid intensification